The next decade could see significant steps towards eradicating viruses which threaten the lives of millions of people worldwide. Major progress has been made towards a cure for hepatitis C, but at $84,000 for a course of treatment, will the cost of the drugs stand in the way of a global roll-out? And with the high cost and risks of toxicity and drug resistance making anti-retrovirals a less than ideal long-term solution for HIV patients, what breakthroughs are giving scientists hope in their efforts to find a cure for the virus?
Join in on Twitter with #c21health
This seminar will be live webcast on YouTube: https://www.youtube.com/watch?v=sN7NwoOQP-s
About the speakers
Dr John Frater is a Principal Investigator in the Institute for Emerging Infections, Oxford Martin School and a Clinical Research Fellow in The Nuffield Department of Medicine at the University of Oxford. John carried out his medical training at Cambridge University and the Royal London Hospital. He undertook a PhD at Imperial College, studying African strains of HIV and their susceptibility to treatment.
Following this he gained a MRC Clinician Scientist Award to work at Oxford University researching HIV evolution and strategies for HIV eradication. He is currently the scientific lead and co-chair of ‘CHERUB’, (Collaborative HIV Eradication of Reservoirs: UK BRC), an NIHR-supported collaboration dedicated to finding a cure for HIV infection. He also works as an Honorary Consultant Physician at the John Radcliffe Hospital in Oxford.
Dr Ellie Barnes is a Principal Investigator in the Institute for Emerging Infections, Oxford Martin School; MRC Senior Clinical Fellow and Honorary Consultant in Hepatology in the Nuffield Department of Medicine, University of Oxford.
Ellie trained in medicine at St. Bartholomew’s hospital, London. Towards the end of her time there she took a year away to study human evolution, social biology and the philosophy of science at University College London. She specialized in liver medicine, attracted to this by the mix of practical and academic skills required. Her PhD was in T cell immunity to hepatitis C virus (HCV) in the context of therapy with Paul Klenerman and Geoff Dusheiko. She has been supported by the MRC (UK) throughout, more recently as a Clinician Scientist at the Peter Medawar Building for pathogen research in Oxford.